# CELEXA — FDA application NDA020822

Informational only - not investment advice.

Application NDA020822 · type NDA · FDA status: approved · original approval 1998-07-17

Listed sponsor: ABBVIE · [ABBV company profile](/company/ABBV/) · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

## FDA application facts

| Product | FDA-listed trade name | Active ingredient | Dosage form | Route | Strength | Marketing status | TE code | RLD |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 001 | CELEXA | CITALOPRAM HYDROBROMIDE | TABLET | ORAL | EQ 10MG BASE | Prescription | AB | Yes |
| 002 | CELEXA | CITALOPRAM HYDROBROMIDE | TABLET | ORAL | EQ 20MG BASE | Prescription | AB | Yes |
| 003 | CELEXA | CITALOPRAM HYDROBROMIDE | TABLET | ORAL | EQ 40MG BASE | Prescription | AB | Yes |
| 004 | CELEXA | CITALOPRAM HYDROBROMIDE | TABLET | ORAL | EQ 60MG BASE | Discontinued | not listed | No |

## Orange Book patent and exclusivity listings

No Orange Book patent or exclusivity listings joined to this application.

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

## Compound cross-links

- CITALOPRAM HYDROBROMIDE · UNII I1E9D14F36 · [lmmol compound WIHMBLDNRMIGDW-UHFFFAOYSA-N](https://lmmol.com/compound/WIHMBLDNRMIGDW-UHFFFAOYSA-N)

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

## Related pages

- [Sponsor company](/company/ABBV/)
- [FDA-approved application index](/drug/)
- [Large-cap biopharma](/compare/pharma/)

Sources: https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files · https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files · https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA020822. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.